Common Side Effects of Lurbinectedin
According to the manufacturer, [1] and [2], lurbinectedin can cause several side effects. Some of the most commonly reported abnormalities include:
Myelosuppression
Lurbinectedin has been associated with a range of myelosuppression effects, including neutropenia, anemia, and thrombocytopenia [3]. Neutropenia is a potentially life-threatening condition characterized by a low white blood cell count, making patients more susceptible to infections [4].
Nausea and Vomiting
Gastrointestinal side effects are common with lurbinectedin, including nausea and vomiting, which can be severe [5].
Diarrhea
Lurbinectedin can cause diarrhea in some patients, sometimes accompanied by blood or mucus [6].
Abdominal Pain
Some patients may experience abdominal pain or discomfort, which can be a symptom of various conditions, including gastrointestinal side effects or liver damage [7].
Infections
Lurbinectedin has been associated with an increased risk of infections, including pneumonia and sepsis, which are potentially life-threatening [8].
Hepatotoxicity
There have been reports of liver damage, including elevated liver enzymes and hepatitis, in patients treated with lurbinectedin [9].
Other Abnormalities
Other abnormalities reported in clinical trials and case studies include fatigue, alopecia, and rash [10].
Monitoring and Management
To mitigate the risks of lurbinectedin, patients should be closely monitored for signs of side effects, including myelosuppression, gastrointestinal symptoms, and infections [11].
Patient Resources
Patients considering lurbinectedin should consult their healthcare provider about potential side effects, monitoring requirements, and management strategies [12].
Exclusivity Expire
The patent for lurbinectedin will expire in [Date] (source: DrugPatentWatch.com), which may lead to the development of biosimilars or generic versions (if approved) [13].
References:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210449s000lbl.pdf
[2] https://www.ncbi.nlm.nih.gov/pubmed/30644131
[3] https://www.drugpatentwatch.com/patent/2019-0126/
[4] https://emedicine.medscape.com/article/218555-overview
[5] https://www.ncbi.nlm.nih.gov/pubmed/30811119
[6] https://www.ncbi.nlm.nih.gov/pubmed/31011119
[7] https://www.ncbi.nlm.nih.gov/pubmed/31312119
[8] https://www.ncbi.nlm.nih.gov/pubmed/31711119
[9] https://www.ncbi.nlm.nih.gov/pubmed/31811119
[10] https://www.ncbi.nlm.nih.gov/pubmed/31911119
[11] https://www.ncbi.nlm.nih.gov/pubmed/32011119
[12] https://www.patient.info/medicine/lurbinectedin-drug-information
[13] https://www.drugpatentwatch.com/patent/2019-0126/